Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $11.00

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRVGet Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $11.6667.

A number of research analysts recently commented on ACRV shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acrivon Therapeutics in a research report on Monday, December 29th. Piper Sandler lifted their target price on Acrivon Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday. Wall Street Zen downgraded Acrivon Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright reissued a “buy” rating and issued a $19.00 target price on shares of Acrivon Therapeutics in a research report on Tuesday, November 25th.

View Our Latest Report on Acrivon Therapeutics

Acrivon Therapeutics Stock Down 9.3%

ACRV stock opened at $1.75 on Monday. The business has a 50 day moving average price of $2.33 and a 200 day moving average price of $1.81. The stock has a market cap of $55.23 million, a price-to-earnings ratio of -0.82 and a beta of 1.73. Acrivon Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $8.00.

Acrivon Therapeutics (NASDAQ:ACRVGet Free Report) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.10. As a group, sell-side analysts anticipate that Acrivon Therapeutics will post -2.49 EPS for the current year.

Hedge Funds Weigh In On Acrivon Therapeutics

Hedge funds have recently modified their holdings of the business. UBS Group AG lifted its position in Acrivon Therapeutics by 150,057.8% during the 3rd quarter. UBS Group AG now owns 683,218 shares of the company’s stock worth $1,237,000 after acquiring an additional 682,763 shares during the period. Jane Street Group LLC acquired a new position in shares of Acrivon Therapeutics in the second quarter valued at approximately $371,000. Two Sigma Investments LP raised its stake in shares of Acrivon Therapeutics by 76.2% during the third quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after purchasing an additional 138,033 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Acrivon Therapeutics during the second quarter worth $126,000. Finally, Algert Global LLC acquired a new stake in shares of Acrivon Therapeutics during the third quarter worth $81,000. 71.62% of the stock is currently owned by hedge funds and other institutional investors.

Acrivon Therapeutics Company Profile

(Get Free Report)

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.

See Also

Analyst Recommendations for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.